Anthem Biosciences IPO: Why India’s Pharma Investors Are Watching Closely

Anthem Biosciences, a Bengaluru-based CRDMO (Contract Research, Development, and Manufacturing Organization), is grabbing headlines across India's pharma and financial sectors. With its ₹3,395 crore IPO now live, there's a growing buzz around investor interest, subscription trends, and grey market premium (GMP) activity.

Company Overview: What Is Anthem Biosciences?

Founded in 2006, Anthem Biosciences has emerged as one of India’s leading CRDMOs. The company delivers a full suite of services from drug discovery to development and manufacturing. It focuses on both New Chemical Entities (NCEs) and New Biological Entities (NBEs).

Its fermentation-based API production includes peptides, biosimilars, enzymes, and probiotics. Anthem has completed more than 8,000 projects and serves clients in over 44 countries, making it a global force in pharmaceutical outsourcing.

IPO Snapshot: Key Details You Should Know

• IPO Size: ₹3,395 crore

• Type: 100% Offer for Sale (OFS)

• Price Band: ₹540–₹570 per share

• Lot Size: 26 shares

• Subscription Window: July 14–16, 2025

• Tentative Listing Date: July 21, 2025

• Registrar: KFin Technologies

• Lead Managers: JM Financial, Citigroup Global Markets India, JP Morgan India, Nomura

Financial Performance: A Look at the Numbers

Anthem Biosciences has shown robust financial growth:

• FY25 Revenue: ₹1,845 crore

• FY25 Net Profit: ₹451 crore

• EBITDA Margin: 36.81%

• Return on Equity (ROE): 20.82%

• Return on Capital Employed (ROCE): 26.88%

This puts Anthem Biosciences ahead of several listed CRDMO peers including Syngene International and Divi’s Laboratories in terms of profitability and scalability.

Investor Sentiment: What the Market Is Saying

As of Day 2 of its IPO:

• Overall Subscription: 77%

• Retail Investors: 0.61x subscribed

• Non-Institutional Investors (NIIs): 1.66x subscribed

• Qualified Institutional Buyers (QIBs): 0.37x subscribed

• Grey Market Premium (GMP): ₹116, indicating a potential listing price of ₹686

The IPO attracted anchor investments worth ₹1,016 crore from leading institutions including Abu Dhabi Investment Authority, Government Pension Fund Global, and several Indian mutual funds.

Why This Is Trending Right Now

There are several reasons this IPO is commanding attention:

• The GMP rose from ₹100 to ₹116 in just 24 hours

• Anthem Biosciences has the largest fermentation capacity in India

• The global CRDMO market is expanding rapidly, and India is becoming a major hub

• Strong anchor investor backing adds credibility and investor confidence

• Financial media and investment platforms are covering it extensively, reflecting heightened awareness

Strategic Strengths of Anthem Biosciences

• Integrated services across the drug lifecycle

• Advanced capabilities in peptides, RNAi, ADCs, and oligonucleotides

• Global client base in North America, Europe, and Asia

• Regulatory approvals from USFDA, EMA, PMDA, and WHO

• Pipeline of 242 active projects and 13 commercial manufacturing contracts

Risks and Considerations

• High dependence on top clients, with over 70% revenue from top five customers

• Premium valuation with a P/E ratio of 70.9x

• High working capital requirements, with net working capital days at 222

• Exposure to global regulatory frameworks and compliance challenges

Frequently Asked Questions (FAQs)

Q: What is the IPO price band of Anthem Biosciences?

A: ₹540–₹570 per share

Q: Is Anthem Biosciences IPO a good investment?

A: Strong fundamentals and growth potential, but investors should evaluate valuation risks

Q: What is the GMP today for Anthem Biosciences IPO?

A: ₹116, indicating a premium of around ₹686 per share

Q: What is the IPO listing date?

A: Tentatively July 21, 2025

Q: What is the minimum investment required?

A: ₹14,820 for one lot of 26 shares

Final Thoughts

Anthem Biosciences is emerging as a major name in the Indian pharmaceutical landscape. Its successful IPO reflects strong investor confidence and sectoral momentum. With advanced capabilities, global client reach, and impressive financials, the company represents a promising long-term growth story.

However, investors must assess valuation risks and operational dependencies before committing capital. For those seeking exposure to high-growth pharmaceutical innovation in India, Anthem Biosciences presents an opportunity worth watching.